Mara De Martino
YOU?
Author Swipe
View article: 902 CD63 as a marker of T cell dysfunction and immune evasion in irradiated glioblastoma
902 CD63 as a marker of T cell dysfunction and immune evasion in irradiated glioblastoma Open
View article: 668 Fatty acid metabolism promotes innate immune evasion and resistance to immunotherapy in irradiated glioblastoma
668 Fatty acid metabolism promotes innate immune evasion and resistance to immunotherapy in irradiated glioblastoma Open
View article: RADIATION-INDUCED LIPID METABOLISM IMPAIRS INNATE IMMUNITY TO PROMOTE GLIOBLASTOMA IMMUNE EVASION
RADIATION-INDUCED LIPID METABOLISM IMPAIRS INNATE IMMUNITY TO PROMOTE GLIOBLASTOMA IMMUNE EVASION Open
AIMS Radiation therapy (RT) can trigger type I interferon (IFN-I) responses and anti-tumor immunity in various can- cers. However, glioblastoma inevitably recurs, suggesting RT does not generate a long-lasting immune response. This may be …
View article: 843 Targeting FASN prevents CD8+ T cell exhaustion in irradiated glioblastoma
843 Targeting FASN prevents CD8+ T cell exhaustion in irradiated glioblastoma Open
View article: 1358 Fatty acid metabolism limits type I interferon responses in irradiated glioblastoma
1358 Fatty acid metabolism limits type I interferon responses in irradiated glioblastoma Open
View article: Cancer cell metabolism and antitumour immunity
Cancer cell metabolism and antitumour immunity Open
View article: Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer Open
View article: 457 Targeting FASN sensitizes irradiated glioblastoma to immune checkpoint blockade
457 Targeting FASN sensitizes irradiated glioblastoma to immune checkpoint blockade Open
Background Radiation therapy (RT), the standard-of-care for glioblastoma, activates cancer cell-intrinsic type I interferon (IFN-I) responses and generates systemic immunity in multiple cancers. However, the combination of RT and immune ch…
View article: Figure S1 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S1 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Gating strategy of intratumoral CD8+ T cells.
View article: Data from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Data from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Increased regulatory T cells (Treg) after radiotherapy have been reported, but the mechanisms of their induction remain incompletely understood. TGFβ is known to foster Treg differentiation within tumors and is activated following radiothe…
View article: Figure S4 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S4 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
INHBA expression correlates with the tumor-infiltrating Treg score in ER positive and negative breast cancer patients.
View article: Figure S3 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S3 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Characterization of Inhba knock-in in TSA cell.
View article: Supplementary Figure Legend from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Supplementary Figure Legend from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Supplementary Figure Legend
View article: Figure S1 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S1 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Gating strategy of intratumoral CD8+ T cells.
View article: Figure S3 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S3 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Characterization of Inhba knock-in in TSA cell.
View article: Figure S2 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S2 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Characterization of Inhba knockdown in 4T1 cells.
View article: Figure S4 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S4 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
INHBA expression correlates with the tumor-infiltrating Treg score in ER positive and negative breast cancer patients.
View article: Supplementary Figure Legend from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Supplementary Figure Legend from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Supplementary Figure Legend
View article: Figure S2 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Figure S2 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Characterization of Inhba knockdown in 4T1 cells.
View article: Data from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Data from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer Open
Increased regulatory T cells (Treg) after radiotherapy have been reported, but the mechanisms of their induction remain incompletely understood. TGFβ is known to foster Treg differentiation within tumors and is activated following radiothe…
View article: Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 repre…
View article: Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab
View article: Supplementary Figure 1 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Supplementary Figure 1 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Figure S1. Aggressive features of tumors overexpressing TNFα. A-C, H&E staining of BT-474 T2 tumors showing A, muscle and B, dermis infiltration (depicted by arrows). C, peritumor leukocyte infiltration (arrow). D, histopatho…
View article: Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We demonstrated that TNFα stimulation in vitro induces trastuzumab res…
View article: Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Revised Supplementary Data
View article: Supplementary Figure Legends from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Supplementary Figure Legends from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Figure Legends
View article: Supplementary Figure 3 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Supplementary Figure 3 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Figure S3. MUC4 expression and outcome of patients with luminal breast cancer respect. Kaplan-Meier analysis of the probability of DFS of patients with luminal breast cancer (HER2-negative, estrogen receptor-positive), based …
View article: Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Revised Supplementary Data
View article: Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 repre…
View article: Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer Open
Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab